登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>CD155 >SCRAJ-STT076

Raji/Human CD155 Stable Cell Line Development Service

For research use only.

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

The Raji/Human CD155 Stable Cell Line was engineered to express full length human CD155 (Gene ID: 5817), used to mimic cancer target cells. When co-cultured with human TIGIT Reporter Cell, the TIGIT/CD155 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the TIGIT/CD155 interaction by either anti-TIGIT or anti-CD155 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.

应用说明(Application)

Useful for cell-based CD155 binding assay

Useful as CD155-expressing target cells in reporter gene assay

CD155 Assay Principles

生长特性(Growth Properties)

Suspension

筛选标记(Selection Marker)

Hygromycin (20 μg/mL)

培养基(Culture Medium)

RPMI-1640 + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

CD155 FACS

Expression analysis of human CD155 on Raji/Human CD155 Stable Cell by FACS.
Raji/Human CD155 Stable Cell Line or negative control cell were stained with PE-labeled anti-Human CD155 antibody.

Protocol

 

Application

CD155 APPLICATION

Blocking activity of anti-human TIGIT antibody.
This Raji/Human CD155 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human TIGIT. The EC50 of anti-human TIGIT antibody was approximately 2.05 μg/mL.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

CD155 is a Type I transmembrane glycoprotein in the immunoglobulin superfamily. Commonly known as Poliovirus Receptor (PVR) due to its involvement in the cellular poliovirus infection in primates, CD155's normal cellular function is in the establishment of intercellular adherens junctions between epithelial cells.

 

Limited Use&License Disclosure

  1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
  2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
  3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
  4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD155靶点信息
英文全称:Poliovirus receptor
中文全称:脊髓灰质炎病毒受体
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:2详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定